AIM
GBT

Acrospire Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Acrospire Investment Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-394
Closed -$15K – 2646
2017
Q1 		$15K Buy
+394
New +$9.92K 0.01% 1752
2016
Q4 		– Sell
-700
Closed -$16K – 2483
2016
Q3 		$16K Sell
700
-800
-53% -$15.2K 0.01% 1582
2016
Q2 		$25K Buy
+1,500
New +$30.3K 0.02% 1456

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Acrospire Investment Management's GBT Position: Q2 2017 in Review

Acrospire Investment Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2017, closing a stake of 394 shares — an estimated $15K sold.

Acrospire Investment Management first reported a position in GBT in Q2 2016 and held it in 3 quarters. The position peaked at $25K in Q2 2016. 134 funds tracked by Wall St. Rank hold GBT as of Q2 2017.

  • Acrospire Investment Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 394 Global Blood Therapeutics, Inc. shares in Q2 2017, an estimated $15K.
  • Acrospire Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Global Blood Therapeutics, Inc. position peaked at $25K in Q2 2016.
  • 134 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.